Cancer Trials Ireland
Quick facts
Marketed products
- Dexamethasone (IV) · Oncology, Immunology, Inflammation
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.
Phase 3 pipeline
- Cisplatin / Oxaliplatin · Oncology
Cisplatin and oxaliplatin are platinum-based chemotherapy agents that bind to DNA and form cross-links, preventing DNA replication and triggering cancer cell death.
Phase 2 pipeline
- Abiraterone acetate, Prednisolone · Oncology
Abiraterone acetate inhibits CYP17A1 to block androgen synthesis, while prednisolone suppresses adrenocorticotropic hormone feedback to further reduce testosterone production in castration-resistant prostate cancer. - Docetaxel, Carboplatin and Trastuzumab
- Docetaxel, Carboplatin, Trastuzumab and Lapatinib
- Radium-223 and enzalutamide
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Cancer Trials Ireland
What are Cancer Trials Ireland's marketed drugs?
Top marketed products include Dexamethasone (IV).
What is Cancer Trials Ireland's pipeline?
Cancer Trials Ireland has 1 drugs in Phase 3, 4 in Phase 2, 0 in Phase 1. Late-stage candidates include Cisplatin / Oxaliplatin.
Related
- Dexamethasone (IV) · Oncology, Immunology, Inflammation
- Sector hub: All tracked pharma companies